Harrow

Harrow has entered into a partnership with Samsung Bioepis to gain exclusive US commercial rights to two FDA-approved ophthalmology biosimilars, BYOOVIZ and OPUVIZ, following Biogen's termination of its commercialization agreement.

• Nordic Pharma, a subsidiary of Nordic Group B.V., has partnered with Harrow to launch an authorized generic version of Maxitrol ophthalmic suspension for treating bacterial eye infections. • The new generic alternative enters a market where Maxitrol and its generic equivalents generated annual sales of $20.8 million in the U.S. as of January 2025, according to IQVIA data. • This product expansion strengthens Nordic Pharma's generic portfolio and aims to provide patients with a more affordable prescription option for treating ocular bacterial infections.

Eyenovia has entered into a non-binding letter of intent with Betaliq to create a new publicly-listed eye care company valued at approximately $92 million, with Betaliq shareholders owning 83.7% of the combined entity.

• Harrow has executed a five-year strategic supply and development agreement with the current contract manufacturing organization for TRIESENCE®, ensuring stable supply of the ocular corticosteroid. • The company has begun developing an enhanced version of TRIESENCE®, with plans to submit a new drug application (NDA) to the FDA by the end of 2027. • TRIESENCE® is FDA-approved for visualization during vitrectomy and treatment of ocular inflammatory conditions unresponsive to topical corticosteroids, addressing a product previously on the FDA's Drug Shortage List.